

1 **Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination**  
2 **in solid organ transplant recipients**

3 Alexandra Tauzin<sup>1,2</sup>, Guillaume Beaudoin-Bussi eres<sup>1,2</sup>, Shang Yu Gong<sup>1,3</sup>, Debashree Chatterjee<sup>1</sup>,  
4 Gabrielle Gendron-Lepage<sup>1</sup>, Catherine Bourassa<sup>1</sup>, Guillaume Goyette<sup>1</sup>, Normand Racine<sup>4</sup>, Zineb Khrifi<sup>1</sup>,  
5 Julie Turgeon<sup>1,5</sup>, C ecile Tremblay<sup>1,2</sup>, Val erie Martel-Laferr iere<sup>1,2</sup>, Daniel E. Kaufmann<sup>1,6</sup>, Marc Cloutier<sup>7</sup>,  
6 Ren ee Bazin<sup>7</sup>, Ralf Duerr<sup>8</sup>, M elanie Dieud e<sup>1,2,5</sup>, Marie-Jos ee H ebert<sup>1,5,6\*</sup>, Andr es Finzi<sup>1,2,3,9,\*</sup>

7 <sup>1</sup>Centre de Recherche du CHUM, Montreal, QC, H2X 0A9 Canada

8 <sup>2</sup>D epartement de Microbiologie, Infectiologie et Immunologie, Universit e de Montr al, Montreal, QC, H2X  
9 0A9, Canada

10 <sup>3</sup>Department of Microbiology and Immunology, McGill University, Montreal, QC, H3A 2B4, Canada

11 <sup>4</sup>Institut Cardiologie de Montr al, Montreal, QC, H1T 1C8, Canada

12 <sup>5</sup>Canadian Donation and Transplantation Research Program (CDTRP), Edmonton, AL, T6G 2E1, Canada

13 <sup>6</sup>D epartement de M edecine, Universit e de Montr al, Montreal, QC, H3T 1J4, Canada

14 <sup>7</sup>H ema-Qu ebec, Affaires M edicales et Innovation, Qu ebec, QC, G1V 5C3, Canada

15 <sup>8</sup>Department of Microbiology, New York University School of Medicine, New York, NY, 10016, USA

16

17

18 <sup>9</sup>Lead contact

19 \*Correspondence: [andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca) (A.F.)

20 [marie-jossee.hebert@umontreal.ca](mailto:marie-jossee.hebert@umontreal.ca) (M.J.H.)

21

22 Summary word count:

23

24 Character count:

25 **SUMMARY**

26 While SARS-CoV-2 mRNA vaccination has been shown to be safe and effective in the  
27 general population, immunocompromised solid organ transplant recipients (SOTR) were reported  
28 to have impaired immune responses after one or two doses of vaccine. In this study, we examined  
29 humoral responses induced after the second and the third dose of mRNA vaccine in different  
30 SOTR (kidney, liver, lung and heart). Compared to a cohort of SARS-CoV-2 naïve  
31 immunocompetent health care workers (HCW), the second dose induced weak humoral  
32 responses in SOTR, except for the liver recipients. The third dose boosted these responses but  
33 they did not reach the same level as in HCW. Interestingly, while the neutralizing activity against  
34 Delta and Omicron variants remained very low after the third dose, Fc-mediated effector functions  
35 in SOTR reached similar levels as in the HCW cohort. Whether these responses will suffice to  
36 protect SOTR from severe outcome remains to be determined.

37

38

39 **KEYWORDS:** Solid organ transplant recipients, Vaccination, Coronavirus, COVID-19, SARS-  
40 CoV-2, Spike glycoproteins, Humoral responses, Neutralization, ADCC, Variants of concern

## 41 INTRODUCTION

42 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent  
43 of the coronavirus disease 2019 (COVID-19) responsible of the current pandemic. COVID-19  
44 causes a plethora of symptoms with different degrees of severity (Sheikhi et al., 2020). In solid  
45 organ transplant recipients (SOTR), due to immunosuppressive treatments, SARS-CoV-2  
46 infection leads to a high rate of severe COVID-19 (Danziger-Isakov et al., 2021; Pereira et al.,  
47 2020) and therefore vaccination is strongly recommended (AST, 2022; CST, 2022). The  
48 Pfizer/BioNTech BNT162b2 and Moderna mRNA-1273 mRNA vaccines have shown a  
49 remarkable efficacy in the general population, particularly against severe outcomes (Baden et al.,  
50 2021; Polack et al., 2020). However, in SOTR, immune responses induced by vaccination are  
51 generally reduced (Kumar et al., 2011; Stucchi et al., 2018) and recent studies have shown that  
52 SOTR have impaired humoral responses after two doses of the SARS-CoV-2 mRNA vaccine  
53 (Caillard et al., 2021; Miele et al., 2021; Rabinowich et al., 2021; Rincon-Arevalo et al., 2021;  
54 Stumpf et al., 2021).

55 Moreover, SARS-CoV-2 is constantly evolving, and the Wuhan original strain has now  
56 been replaced by several variants. Among current circulating strains, the Delta and Omicron  
57 variants of concern (VOCs) have accumulated numerous mutations in their genome, and notably  
58 in the Spike (S) glycoprotein (Kumar et al., 2022). Because of the mutations, these VOCs are  
59 transmitted more efficiently than the original Wuhan strain and less well controlled by vaccination  
60 (Kumar et al., 2022; Luring et al., 2022; Tseng et al., 2022). However, the administration of a  
61 third dose of mRNA vaccine (boost) leads to strong humoral responses and protects from severe  
62 outcome caused by these VOCs in the general population (Ariën et al., 2022; Tauzin et al., 2022a;  
63 Yoon et al., 2022). However, humoral responses elicited by the third dose on populations with  
64 compromised immune responses, particularly SOTR, are less documented. Here, we evaluated

65 humoral responses induced in different groups of SOTR (kidney, liver, lung and heart) after the  
66 second and third doses of the mRNA vaccine.

## 67 RESULTS

68 We analyzed humoral immune responses in cohorts of 31 kidney, 11 liver, 14 lung and 8  
69 heart organ transplant recipients after the second (median [range]: 26 days [20–54 days]) and  
70 third doses (median [range]: 35 days [19–68 days]) of SARS-CoV-2 mRNA vaccine. The SOTR  
71 received their first two doses with different interval regimen (median [range]: 36 days [25–112  
72 days]) and their third dose around 4 months after the second dose (median [range]: 110 days  
73 [34–195 days]), according to the province of Quebec, Canada public health authority’s vaccination  
74 roll out guidelines for immunocompromised patients. Vaccine-elicited humoral responses in  
75 SOTR were compared to those measured in a cohort of SARS-CoV-2 naïve health care workers  
76 (HCW). HCW received their first two doses of mRNA vaccine with a 16-week extended interval  
77 (median [range]: 111 days [76–134 days]), and their third dose around seven months after the  
78 second dose (median [range]: 219 days [167-235 days]), according to the province of Quebec,  
79 Canada public health authority’s vaccination roll out guidelines for HCW. Several studies have  
80 shown that this extended interval regimen leads to strong humoral and cellular responses after  
81 the second dose, notably against VOCs (Chatterjee et al., 2022; Nayrac et al., 2021; Payne et al.,  
82 2021; Tauzin et al., 2022a). This allowed us to compare humoral responses obtained in SOTR  
83 versus humoral responses elicited by a long interval vaccination regimen. Basic demographic  
84 characteristics of the cohorts, immunosuppressive treatments of the SOTR and detailed  
85 vaccination time points are summarized in Table 1 and Figure 1A.

86

### 87 **Elicitation of SARS-CoV-2 antibodies against the receptor-binding domain of the Spike**

88 We first measured anti-receptor-binding domain (RBD) IgG levels induced after the  
89 second and the third doses of the mRNA vaccine using a previously reported ELISA assay (Anand  
90 et al., 2021; Beaudoin-Bussièrès et al., 2020; Prévost et al., 2020; Tauzin et al., 2021). After the  
91 second dose, all HCW presented high levels of RBD-specific IgG (Figure 1B). In contrast, in all

92 groups of SOTR, the levels of anti-RBD antibodies (Abs) were, with the exception of liver  
93 recipients, significantly lower than in HCW. We also noted that in every SOTR group, some donors  
94 did not have anti-RBD IgG after the second dose of mRNA vaccine. Among SOTR, liver recipients  
95 had higher Ab levels than kidney, lung and heart recipients, in line with a generally lower  
96 immunosuppression regimen. For HCW, the third dose of the mRNA vaccine led to the same level  
97 of Abs as after the second dose, as recently described (Tauzin et al., 2022a). For SOTR, we  
98 observed a significant increase in the level of anti-RBD IgG in lung recipients and a trend for  
99 kidney and heart recipients. No increase in anti-RBD IgG level was observed for liver recipients.  
100 Of note, in all SOTR groups, anti-RBD levels remained significantly lower than in the HCW cohort  
101 even after the third dose, but most donors who did not have anti-RBD IgG after the second dose  
102 developed antibodies after the third dose, suggesting the initiation of an antibody response by  
103 repeated antigen exposure.

104

#### 105 **Recognition of SARS-CoV-2 Spike variants and a common-cold human *Betacoronavirus***

106 We next evaluated the recognition of the SARS-CoV-2 full-length S after vaccination in  
107 SOTR and HCW by flow cytometry (Figure 2A). After the second vaccine dose, no significant  
108 differences were observed in the recognition of the D614G S by plasma from kidney and liver  
109 recipients and HCW. In contrast, lung and heart recipients recognized the D614G S less  
110 efficiently. The third dose increased the D614G S recognition for HCW, and we noted a slight  
111 increase for lung and heart recipients, for whom the recognition was very weak after the second  
112 dose. For kidney and liver recipients, the third dose did not improve the D614G S recognition  
113 (Figure 2A).

114 It has been well documented that Delta and Omicron VOCs are less efficiently recognized  
115 by Abs induced by vaccination, because of accumulated mutations in the S glycoproteins  
116 compared to the original Wuhan strain, used for the development of current mRNA SARS-CoV-2  
117 vaccines (Chatterjee et al., 2022; Planas et al., 2021; Tauzin et al., 2022a). We measured the

118 recognition of these VOCs S after mRNA vaccination in SOTR (Figure 2B-C). We did not see  
119 significant differences in the level of recognition of Delta and Omicron S between liver recipients  
120 and HCW after the second dose. The third dose led to a slight increase of the recognition of the  
121 VOCs S except for liver recipients, however it remained significantly lower than in HCW. When  
122 we compared S recognition between the SARS-CoV-2 variants (Figure S1), we observed that in  
123 HCW, because of strong humoral responses induced by the extended interval, no major  
124 differences in recognition were observed between D614G and VOCs S after the second and third  
125 doses of mRNA vaccine (Figure S1A). For SOTR, VOCs S were significantly less recognized than  
126 the D614G S, suggesting that vaccination in SOTR did not improve the breadth of S recognition,  
127 as observed in HCW (Figure S1B-E).

128 We also evaluated the recognition of the human HKU1 *Betacoronavirus* S glycoprotein  
129 (Figure 2D). HKU1 is an endemic coronavirus that causes common colds and is highly prevalent  
130 in the population (Chan et al., 2009; Rees et al., 2021). No significant differences between HCW  
131 and SOTR were observed after the second and the third doses of the vaccine, indicating that  
132 transplantation and associated immunosuppression regimens did not affect the level of circulating  
133 Abs elicited before vaccination.

134

### 135 **Functional activities of vaccine-elicited antibodies**

136 We evaluated functional activities of vaccine-elicited Abs after the second and third doses  
137 of mRNA vaccine (Figure 3). We measured Fc-mediated effector functions using a well-described  
138 antibody-dependent cellular cytotoxicity (ADCC) assay (Anand et al., 2021; Beaudoin-Bussi eres  
139 et al., 2020, 2021; Ullah et al., 2021). Plasma from HCW presented robust ADCC activity after  
140 the second dose that was restored to the same level by the third dose (Figure 3A). The second  
141 dose elicited ADCC-mediating Abs in liver and heart recipients that reached similar levels of  
142 activity as in HCW. This is in contrast with significant lower ADCC activity elicited after the second  
143 dose in kidney and lung recipients. The boost led to a significant increase in ADCC activity in

144 these donors. Importantly, the third dose elicited ADCC activity in all SOTR similar to the one  
145 observed in HCW.

146 We also measured the neutralizing activity of the vaccine-induced Abs, against  
147 pseudoviruses carrying SARS-CoV-2 S (Figure 3B-D). When assessing the neutralizing activity  
148 against the D614G S, we observed that the second dose elicited Abs with neutralizing activity in  
149 liver recipients (Figure 3B). In other SOTR, very low levels of neutralizing Abs were detected,  
150 especially in lung recipients. As observed for ADCC activity, the boost increased the neutralization  
151 activity in kidney and lung recipients. However, even after the third dose, SOTR did not reach the  
152 same levels of neutralizing Abs as in HCW.

153 We also measured the neutralizing activity against pseudoviruses carrying the Delta and  
154 Omicron Spikes (Figure 3C-D). In HCW, the second dose of mRNA vaccine administered with a  
155 16-weeks interval, led to high levels of Abs able to neutralize these variants, as previously  
156 described (Chatterjee et al., 2022; Payne et al., 2021; Tausin et al., 2022a). In contrast, SOTR  
157 elicited very low levels of neutralizing Abs against Delta and Omicron variants after the second  
158 dose and, although the boost led to a slight increase of the neutralization activity, this remained  
159 significantly lower than in HCW.

160 When comparing the neutralizing activity between the SARS-CoV-2 variants (Figure S2),  
161 Delta was less efficiently neutralized in HCW than D614G at the two different time points (Figure  
162 S2A). For kidney and liver recipients, Omicron and Delta VOCs were less neutralized than D614G  
163 (Figure S2B-C). For other SOTR, neutralization activity was too weak to measure significant  
164 differences (Figure S2D-E).

165

### 166 **Anti-RBD avidity of vaccine-elicited antibodies**

167 We also used a surrogate assay for antibody maturation by measuring the avidity for the  
168 RBD of vaccine-elicited Abs, using a previously described assay (Björkman et al., 1999; Fialová  
169 et al., 2017; Tausin et al., 2022a, 2022b, 2022c). Briefly, plasma samples were tested in parallel



170 by ELISA with washing steps having or not having a chaotropic agent (8M urea), measuring  
171 respectively the level of IgG with high avidity for the RBD and the level of total anti-RBD IgG. The  
172 RBD-avidity index corresponds to the proportion of high avidity IgG among the total anti-RBD IgG  
173 (Figures 4), and provides an overall idea of antibody maturation (Björkman et al., 1999; Fialová  
174 et al., 2017; Tauzin et al., 2022a, 2022b, 2022c).

175

176 In HCW, the second dose of the mRNA vaccine elicited IgG with high avidity, that was not  
177 further improved by the boost (Figure 4), as recently described (Tauzin et al., 2022a). In contrast,  
178 in SOTR who developed Abs able to recognize the RBD, the avidity was significantly lower than  
179 in HCW (Figure 1B and 4). The third dose of mRNA vaccine increased RBD avidity in SOTR but,  
180 with the exception of liver recipients, remained significantly lower than in HCW.

181

## 182 **Integrated analysis of vaccine responses elicited in solid organ transplant recipients**

183 We evaluated the network of pairwise correlations among all studied immune variables on  
184 the HCW and the different SOTR groups (Figure 5). For HCW, we observed that after the second  
185 dose all immune variables tested were involved in a dense network of positive correlations. After  
186 the boost, we did not observe major differences in the network of correlations, suggesting that the  
187 third dose did not induce qualitatively different humoral responses in HCW. For lung and heart  
188 recipients, who received the strongest immunosuppressive regimens, we observed that all  
189 immune variables were very weakly interconnected after the second dose and the third dose did  
190 not strongly increase the network. Immune variables were slightly more interconnected for kidney  
191 recipients, which aligns with their lower immunosuppressive regimen compared to heart and lung  
192 recipients. For liver recipients, the network of correlation was less dense than in HCW after the  
193 second dose as observed for the other groups of SOTR. Interestingly, in this less  
194 immunosuppressed group of SOTR, the third dose of the mRNA vaccine induced a dense network  
195 of correlations, which was in a comparable range as in HCW.

196 **DISCUSSION**

197           While a large part of the world population is vaccinated with two or three doses of SARS-  
198 CoV-2 vaccines, some population groups remain vulnerable to SARS-CoV-2 infection and most  
199 importantly to severe outcomes. Here we show that SOTR, known to respond less efficiently to  
200 vaccination due to their chronic immunosuppressive regimen (Kumar et al., 2011; Stucchi et al.,  
201 2018), elicited poor humoral responses after the second dose of SARS-CoV-2 mRNA vaccine,  
202 compared to HCW. The boost induced an increase of these responses, but they did not reach the  
203 same level as observed in HCW.

204  
205           An important concern about the evolving pandemic is the frequent apparition of variants.  
206 It was previously shown that the 3-4 weeks standard interval of vaccination leads to weak  
207 neutralizing Abs against several VOCs in the general population (Chatterjee et al., 2022; Payne  
208 et al., 2021; Tazuin et al., 2022a, 2022c). However, administering a boost strongly enhances the  
209 breadth of neutralization activity against these variants (Nemet et al., 2022; Schmidt et al., 2022;  
210 Tazuin et al., 2022a). In SOTR, we did not observe a significant increase in the breadth of  
211 recognition and neutralization of these variants, suggesting an inability in Abs maturation in most  
212 of these individuals. This is supported by the poor anti-RBD avidity detected in these individuals,  
213 likely reflecting poor B cells maturation compared to HCW.

214  
215           Interestingly, we observed that SOTR elicited Abs with ADCC activity comparable to HCW  
216 after the third dose of the mRNA vaccine. There is increasing evidence showing that Fc-mediated  
217 effector functions play an important role in the protection against severe outcomes of SARS-CoV-  
218 2 (Anand et al., 2021; Richardson et al., 2022; Tazuin et al., 2021). However, whether this will  
219 suffice to protect SOTR from severe outcomes caused by SARS-CoV-2 remains unknown.

220

221 We also noted some differences in humoral responses, depending on the transplanted  
222 organ. Notably, we observed that liver recipients had better humoral responses than other SOTR  
223 groups. These differences are probably due to the lower immunosuppressive regimens in liver  
224 recipients than in other SOTR groups. Further work is needed to understand the correlation  
225 between specific immunosuppressive regimens and vaccination outcome, taking into account the  
226 dose and type of immunosuppressive agents, and response to SARS-CoV-2 vaccines. This also  
227 highlights the importance of evaluating the different SOTR groups independently regarding the  
228 decisions on the follow-up of vaccinations that needs to be adapted to each SOTR group.

229

230

## 231 **ACKNOWLEDGMENTS**

232 The authors are grateful to the donors who participated in this study. The authors thank  
233 the CRCHUM BSL3 and Flow Cytometry Platforms for technical assistance. We thank Dr. M.  
234 Gordon Joyce (U.S. MHRP) for the monoclonal antibody CR3022. We also thank Demitra Yotis,  
235 Amani Mahroug, Yizou Zhao and Annie Karakeussian Rimbaud for their contribution on the  
236 transplant cohort. The graphical abstract was created using BioRender.com. This work was  
237 supported by le Ministère de l'Économie et de l'Innovation du Québec, Programme de soutien  
238 aux organismes de recherche et d'innovation to A.F. and by the Fondation du CHUM. This work  
239 was also supported by a CIHR foundation grant #352417, by a CIHR operating Pandemic and  
240 Health Emergencies Research grant #177958, to A.F., and by an Exceptional Fund COVID-19  
241 from the Canada Foundation for Innovation (CFI) #41027 to D.E.K. and A.F. This work was also  
242 supported by a FRQS Pandemic Initiatives COVID-19 grant #308941 to M.J.H and in-kind  
243 contribution from Canadian Donation and Transplantation Research Program (CDTRP). Work on  
244 variants presented was also supported by the Sentinelle COVID Quebec network led by the LSPQ  
245 in collaboration with Fonds de Recherche du Québec Santé (FRQS) to A.F. A.F. is the recipient

246 of Canada Research Chair on Retroviral Entry no. RCHS0235 950-232424. M.-J. H. holds the  
247 Shire Chair in Nephrology, Transplantation and Renal Regeneration of Université de Montréal.  
248 C.T holds the Pfizer/Université de Montréal Chair on HIV translational research. V.M.L. is  
249 supported by a FRQS Junior 1 salary award. D.E.K. is a FRQS Merit Research Scholar. G.B.B.  
250 is the recipient of a FRQS PhD fellowship. The funders had no role in study design, data collection  
251 and analysis, decision to publish, or preparation of the manuscript. We declare no competing  
252 interests.

253

#### 254 **AUTHOR CONTRIBUTIONS**

255 A.T., M.D., M.J.H. and A.F. conceived the study. A.T., G.B.B., S.Y.G., D.C., C.B., P.L.,  
256 G.G.L. M.D., M.J.H. and A.F. performed, analyzed, and interpreted the experiments. A.T. and  
257 R.D. performed statistical analysis. G.B.B., S.Y.G., G.G.L., G.G., J.T., M.D., M.J.H. and A.F.  
258 contributed unique reagents. N.R., Z.K. C.T., D.E.K., M.J.H. and V.M.-L. collected and provided  
259 clinical samples. D.E.K., M.C., R.B., M.D., M.J.H. and A.F provided scientific input. A.T., and A.F.  
260 wrote the manuscript with inputs from others. Every author has read, edited, and approved the  
261 final manuscript.

262

#### 263 **DECLARATION OF INTERESTS**

264 The authors declare no competing interests.

265

266 **FIGURE LEGENDS**

267 **Figure 1. Elicitation of RBD-specific antibodies in SOTR and HCW after mRNA vaccination.**

268 (A) SARS-CoV-2 vaccine cohorts' design. (B) Indirect ELISA was performed by incubating  
269 plasma samples from SOTR or HCW with recombinant SARS-CoV-2 RBD protein. Anti-RBD Ab  
270 binding was detected using HRP-conjugated anti-human IgG. Relative light unit (RLU) values  
271 obtained with BSA (negative control) were subtracted and further normalized to the signal  
272 obtained with the anti-RBD CR3022 mAb presents in each plate. **Left panel** shows the values  
273 obtained after the second dose, and **middle panel** after the third dose. **Right panel** shows the  
274 difference obtained between D2 (post second dose) and D3 (post third dose) for every group.  
275 Symbols represent biologically independent samples from SOTR and HCW. Lines connect data  
276 from the same donor. Undetectable measures are represented as white symbols, and limits of  
277 detection are plotted. Error bars indicate means  $\pm$  SEM. (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ; \*\*\*\*  
278  $p < 0.0001$ ; ns, non-significant).

279

280 **Figure 2. Binding of vaccine-elicited antibodies to SARS-CoV-2 Spike variants and the**  
281 **human HKU1 *Betacoronavirus* in SOTR and HCW after mRNA vaccination.**

282 293T cells were transfected with the indicated full-length S from different SARS-CoV-2 variants  
283 and HCoV-HKU1 and stained with the CV3-25 Ab or with plasma from SOTR or HCW. The values  
284 represent the median fluorescence intensities (MFI) normalized by CV3-25 Ab binding (A-C) or  
285 the MFI (D). **Left panel** shows the values obtained after the second dose, and **middle panel** after  
286 the third dose. **Right panel** shows the differences obtained between D2 (post second dose) and  
287 D3 (post third dose) for every group. Symbols represent biologically independent samples from  
288 SOTR and HCW. Lines connect data from the same donor. Undetectable measures are

289 represented as white symbols, and limits of detection are plotted. Error bars indicate means  $\pm$   
290 SEM. (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ; \*\*\*\*  $p < 0.0001$ ; ns, non-significant).

291  
292 **Figure 3. Fc-mediated effector functions and neutralization activities in SOTR and HCW**  
293 **after mRNA vaccination.**

294 (A) CEM.NKr parental cells were mixed at a 1:1 ratio with CEM.NKr-Spike cells and were used  
295 as target cells. PBMCs from uninfected donors were used as effector cells in a FACS-based  
296 ADCC assay. (B-D) Neutralizing activity was measured by incubating pseudoviruses bearing  
297 SARS-CoV-2 S glycoproteins ((B) D614G, (C) Delta and (D) Omicron), with serial dilutions of  
298 plasma for 1 h at 37°C before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory  
299 serum dilution (ID<sub>50</sub>) values were determined using a normalized non-linear regression using  
300 GraphPad Prism software. **Left panel** shows the values obtained after the second dose, and  
301 **middle panel** after the third dose. **Right panel** shows the differences obtained between D2 (post  
302 second dose) and D3 (post third dose) for every group. Symbols represent biologically  
303 independent samples from SOTR and HCW. Lines connect data from the same donor.  
304 Undetectable measures are represented as white symbols, and limits of detection are plotted.  
305 Error bars indicate means  $\pm$  SEM. (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ; \*\*\*\*  $p < 0.0001$ ; ns, non-  
306 significant).

307  
308 **Figure 4. Anti-RBD avidity of vaccine-elicited antibodies in SOTR and HCW after mRNA**  
309 **vaccination.**

310 Indirect ELISA and stringent ELISA were performed by incubating plasma samples from SOTR  
311 and HCW with recombinant SARS-CoV-2 RBD protein. Anti-RBD Ab binding was detected using  
312 HRP-conjugated anti-human IgG. The RBD avidity index corresponded to the RLU value obtained

313 for every plasma sample with the stringent (8M urea) ELISA divided by that obtained with the 0M  
314 urea ELISA. **Left panel** shows the values obtained after the second dose, and **middle panel** after  
315 the third dose. **Right panel** shows the differences obtained between D2 (post second dose) and  
316 D3 (post third dose) for every group. Symbols represent biologically independent samples from  
317 SOTR and HCW. Lines connect data from the same donor. Undetectable measures are  
318 represented as white symbols, and limits of detection are plotted. Error bars indicate means  $\pm$   
319 SEM. (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*\*  $p < 0.0001$ ; ns, non-significant).

320

321 **Figure 5. Mesh correlations of humoral response variables in SOTR and HCW after mRNA**  
322 **vaccination.**

323 Edge bundling correlation plots where red and blue edges represent positive and negative  
324 correlations between connected variables, respectively. Only significant correlations ( $p < 0.05$ ,  
325 Spearman rank test) are displayed. Nodes are color coded based on the grouping of variables  
326 according to the legend. Node size corresponds to the degree of relatedness of correlations. Edge  
327 bundling plots are shown for correlation analyses using ten different datasets, i.e., HCW and  
328 kidney, liver, lung or heart transplant recipients after the second and third doses of mRNA  
329 vaccination.

330

331

332

**Table 1. Characteristics of the SARS-CoV-2 vaccinated SOTR and HCW cohorts**

		HCW	SOTR				
			Entire cohort	Kidney	Liver	Lung	Heart
<b>Age</b>		52 (33 - 64)	46 (21 - 82)	46 (23 - 73)	44 (21 - 59)	38 (26 - 59)	66 (58 - 82)
<b>Sex</b>	<b>Male (n)</b>	8	39	19	7	7	6
	<b>Female (n)</b>	12	25	12	4	7	2
<b>Immunosuppression</b>	<b>Prednisone (n)</b>	N/A	47	30	4	13	0
	<b>Tacrolimus (n)</b>	N/A	58	28	10	14	6
	<b>Mycophenolate mofetil/mucophenolate sodium (n)</b>	N/A	49	26	2	13	8
	<b>Cyclosporin (n)</b>	N/A	2	1	0	0	1
	<b>Sirolimus (n)</b>	N/A	4	2	1	0	1
	<b>Azathioprine (n)</b>	N/A	4	1	2	1	0
<b>Years between transplantation and the 1<sup>st</sup> dose<sup>a</sup></b>		N/A	3.90 (-0.40 – 36.28)	2.04 (-0.40 – 22.93)	3.50 (0.66 – 36.28)	3.66 (0.36 – 20.07)	11.41 (3.20 – 23.65)
<b>Days between the 1<sup>st</sup> and 2<sup>nd</sup> dose<sup>a</sup></b>		111 (76-120)	36 (25 – 112)	34 (28 – 75)	37 (28 – 112)	32 (25 – 92)	84 (62 – 101)
<b>Days between the 2<sup>nd</sup> and 3<sup>rd</sup> dose<sup>a</sup></b>		219 (167-230)	110 (34 - 195)	111 (34 - 153)	113 (74 -147)	104 (81 - 169)	81 (78 - 195)
<b>Days between the 2<sup>nd</sup> dose and D2<sup>a</sup></b>		21 (17-34)	26 (20 - 54)	27 (22 - 45)	26 (22 - 35)	26 (22 - 28)	28 (20 - 54)
<b>Days between the 3<sup>rd</sup> dose and D3<sup>a</sup></b>		27 (20-38)	35 (19 - 68)	35 (19 - 48)	35 (21 - 55)	42 (28 - 68)	30 (22 - 51)

333

<sup>a</sup> Values displayed are medians, with ranges in parentheses.

334



335 **STAR METHODS**

336

337 **RESOURCE AVAILABILITY**

338

339 **Lead contact**

340 Further information and requests for resources and reagents should be directed to and will be  
341 fulfilled by the lead contact, Andrés Finzi ([andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca)).

342

343 **Materials availability**

344 All unique reagents generated during this study are available from the Lead contact without  
345 restriction.

346

347 **Data and code availability**

348 • All data reported in this paper will be shared by the lead contact  
349 ([andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca)) upon request.

350 • This paper does not report original code.

351 • Any additional information required to reanalyze the data reported in this paper is available  
352 from the lead contact ([andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca)) upon request.

353

354

## 355 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

356

### 357 **Ethics Statement**

358 All work was conducted in accordance with the Declaration of Helsinki in terms of informed  
359 consent and approval by an appropriate institutional board. Blood samples were obtained from  
360 donors who consented to participate in this research project at CHUM (19.381 and 21.001).  
361 Plasmas were isolated by centrifugation and Ficoll gradient, and samples stored at -80°C until  
362 use.

### 363 **Human subjects**

364 The study was conducted in 20 SARS-CoV-2 naïve vaccinated HCW (8 males and 12 females;  
365 age range: 33-64 years) and 64 SARS-CoV-2 vaccinated SOTR (39 males and 25 females; age  
366 range: 21-82 years). All this information is summarized in table 1. For SARS-CoV-2 naïve  
367 vaccinated HCW cohort, no specific criteria such as number of patients (sample size), gender,  
368 clinical or demographic were used for inclusion, beyond no detection of Abs recognizing the N  
369 protein. For SARS-CoV-2 vaccinated SOTR, greater than 1-month post-transplant at the time of  
370 enrolment was used for inclusion.

371

### 372 **Plasma and antibodies**

373 Plasma from SOTR and HCW were collected, heat-inactivated for 1 hour at 56°C and stored at -  
374 80°C until ready to use in subsequent experiments. Plasma from uninfected donors collected  
375 before the pandemic were used as negative controls and used to calculate the seropositivity  
376 threshold in our ELISA, ADCC and flow cytometry assays (see below). The RBD-specific  
377 monoclonal antibody CR3022 was used as a positive control in our ELISA, and the CV3-25  
378 antibody in flow cytometry assays and were previously described (Anand et al., 2020; Beaudoin-  
379 Bussièrès et al., 2020; Jennewein et al., 2021; Meulen et al., 2006; Prévost et al., 2020).

380 Horseradish peroxidase (HRP)-conjugated Abs able to recognize the Fc region of human IgG  
381 (Invitrogen) were used as secondary Abs in ELISA experiments. Alexa Fluor-647-conjugated goat  
382 anti-human Abs able to detect all Ig isotypes (anti-human IgM+IgG+IgA; Jackson  
383 ImmunoResearch Laboratories) were used as secondary Abs to detect plasma binding in flow  
384 cytometry experiments.

385

### 386 **Cell lines**

387 293T human embryonic kidney cells (obtained from ATCC) were maintained at 37°C under 5%  
388 CO<sub>2</sub> in Dulbecco's modified Eagle's medium (DMEM) (Wisent) containing 5% fetal bovine serum  
389 (FBS) (VWR) and 100 µg/ml of penicillin-streptomycin (Wisent). CEM.NKr CCR5+ cells (NIH AIDS  
390 reagent program) and CEM.NKr.Spike cells were maintained at 37°C under 5% CO<sub>2</sub> in Roswell  
391 Park Memorial Institute (RPMI) 1640 medium (Gibco) containing 10% FBS and 100 µg/ml of  
392 penicillin-streptomycin. 293T-ACE2 cell line was previously reported (Prévost et al., 2020).  
393 CEM.NKr CCR5+ cells stably expressing the SARS-CoV-2 S glycoprotein were previously  
394 reported (Anand et al., 2021; Beaudoin-Bussièrès et al., 2021).

395

### 396 **METHOD DETAILS**

#### 397 **Plasmids**

398 The HCoV-HKU1 S expressing plasmid was purchased from Sino Biological. The plasmids  
399 encoding the different SARS-CoV-2 Spike variants (D614G, Delta and Omicron) were previously  
400 described (Beaudoin-Bussièrès et al., 2020; Chatterjee et al., 2022; Gong et al., 2021; Tauzin et  
401 al., 2021, 2022c).

402

#### 403 **Protein expression and purification**

404 FreeStyle 293F cells (Invitrogen) were grown in FreeStyle 293F medium (Invitrogen) to a density  
405 of 1 x 10<sup>6</sup> cells/mL at 37°C with 8 % CO<sub>2</sub> with regular agitation (150 rpm). Cells were transfected

406 with a plasmid coding for SARS-CoV-2 S RBD (Beaudoin-Bussi eres et al., 2020) using  
407 ExpiFectamine 293 transfection reagent, as directed by the manufacturer (Invitrogen). One week  
408 later, cells were pelleted and discarded. Supernatants were filtered using a 0.22 µm filter (Thermo  
409 Fisher Scientific). The recombinant RBD proteins were purified by nickel affinity columns, as  
410 directed by the manufacturer (Invitrogen). The RBD preparations were dialyzed against  
411 phosphate-buffered saline (PBS) and stored in aliquots at -80°C until further use. To assess  
412 purity, recombinant proteins were loaded on SDS-PAGE gels and stained with Coomassie Blue.  
413

#### 414 **Enzyme-Linked Immunosorbent Assay (ELISA) and RBD avidity index**

415 The SARS-CoV-2 RBD ELISA assay used was previously described (Beaudoin-Bussi eres et al.,  
416 2020; Pr evost et al., 2020). Briefly, recombinant SARS-CoV-2 S RBD proteins (2.5 µg/ml) were  
417 prepared in PBS and were adsorbed to plates (MaxiSorp Nunc) overnight at 4°C. Coated wells  
418 were subsequently blocked with blocking buffer (Tris-buffered saline [TBS] containing 0.1%  
419 Tween20 and 2% BSA) for 1h at room temperature. Wells were then washed four times with  
420 washing buffer (Tris-buffered saline [TBS] containing 0.1% Tween20). CR3022 mAb (50 ng/ml)  
421 or a 1/250 dilution of plasma were prepared in a diluted solution of blocking buffer (0.1 % BSA)  
422 and incubated with the RBD-coated wells for 90 minutes at room temperature. Plates were  
423 washed four times with washing buffer followed by incubation with secondary Abs (diluted in a  
424 solution of blocking buffer (0.4% BSA)) for 1h at room temperature, followed by four washes. To  
425 calculate the RBD-avidity index, we performed in parallel a stringent ELISA, where the plates  
426 were washed with a chaotropic agent, 8M of urea, added of the washing buffer. This assay was  
427 previously described (Tauzin et al., 2022b). HRP enzyme activity was determined after the  
428 addition of a 1:1 mix of Western Lightning oxidizing and luminol reagents (Perkin Elmer Life  
429 Sciences). Light emission was measured with a LB942 TriStar luminometer (Berthold  
430 Technologies). Signal obtained with BSA was subtracted for each plasma and was then  
431 normalized to the signal obtained with CR3022 present in each plate. The seropositivity threshold

432 was established using the following formula: mean of pre-pandemic SARS-CoV-2 negative  
433 plasma + (3 standard deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma).

434

#### 435 **Cell surface staining and flow cytometry analysis**

436 293T cells were co-transfected with a GFP expressor (pIRES2-GFP, Clontech) in combination  
437 with plasmid encoding the full-length S of SARS-CoV-2 variants (D614G, Delta or Omicron) or  
438 the HCoV-HKU1 S. 48h post-transfection, S-expressing cells were stained with the CV3-25 Ab  
439 (Jennewein et al., 2021) or plasma (1/250 dilution). Alexa Fluor-647-conjugated goat anti-human  
440 IgM+IgG+IgA Abs (1/800 dilution) were used as secondary Abs. The percentage of transfected  
441 cells (GFP+ cells) was determined by gating the living cell population based on viability dye  
442 staining (Aqua Vivid, Invitrogen). Samples were acquired on a LSRII cytometer (BD Biosciences),  
443 and data analysis was performed using FlowJo v10.7.1 (Tree Star). The seropositivity threshold  
444 was established using the following formula: (mean of pre-pandemic SARS-CoV-2 negative  
445 plasma + (3 standard deviation of the mean of pre-pandemic SARS-CoV-2 negative plasma). The  
446 conformational-independent S2-targeting mAb CV3-25 was used to normalize Spike expression  
447 and was shown to effectively recognize all SARS-CoV-2 Spike variants (Li et al., 2022).

448

#### 449 **ADCC assay**

450 This assay was previously described (Anand et al., 2021; Beaudoin-Bussi eres et al., 2021). For  
451 evaluation of anti-SARS-CoV-2 ADCC, parental CEM.NKr CCR5+ cells were mixed at a 1:1 ratio  
452 with CEM.NKr cells stably expressing a GFP-tagged full length SARS-CoV-2 Spike  
453 (CEM.NKr.SARS-CoV-2.Spike cells). These cells were stained for viability (AquaVivid; Thermo  
454 Fisher Scientific, Waltham, MA, USA) and cellular dyes (cell proliferation dye eFluor670; Thermo  
455 Fisher Scientific) to be used as target cells. Overnight rested PBMCs were stained with another  
456 cellular marker (cell proliferation dye eFluor450; Thermo Fisher Scientific) and used as effector  
457 cells. Stained target and effector cells were mixed at a ratio of 1:10 in 96-well V-bottom plates.

458 Plasma (1/500 dilution) were added to the appropriate wells. The plates were subsequently  
459 centrifuged for 1 min at 300g, and incubated at 37°C, 5% CO<sub>2</sub> for 5 hours before being fixed in a  
460 2% PBS-formaldehyde solution. ADCC activity was calculated using the formula: [(% of GFP+  
461 cells in Targets plus Effectors)-( % of GFP+ cells in Targets plus Effectors plus  
462 plasma/antibody)]/(% of GFP+ cells in Targets) x 100 by gating on transduced live target cells. All  
463 samples were acquired on an LSRII cytometer (BD Biosciences) and data analysis was performed  
464 using FlowJo v10.7.1 (Tree Star). The specificity threshold was established using the following  
465 formula: (mean of pre-pandemic SARS-CoV-2 negative plasma + (3 standard deviation of the  
466 mean of pre-pandemic SARS-CoV-2 negative plasma).

467

#### 468 **Virus neutralization assay**

469 To produce the pseudoviruses, 293T cells were transfected with the lentiviral vector pNL4.3 R-E-  
470 Luc (NIH AIDS Reagent Program) and a plasmid encoding for the indicated S glycoprotein  
471 (D614G, Delta or Omicron) at a ratio of 10:1. Two days post-transfection, cell supernatants were  
472 harvested and stored at -80°C until use. For the neutralization assay, 293T-ACE2 target cells  
473 were seeded at a density of 1×10<sup>4</sup> cells/well in 96-well luminometer-compatible tissue culture  
474 plates (Perkin Elmer) 24h before infection. Pseudoviral particles were incubated with several  
475 plasma dilutions (1/50; 1/250; 1/1250; 1/6250; 1/31250) for 1h at 37°C and were then added to  
476 the target cells followed by incubation for 48h at 37°C. Then, cells were lysed by the addition of  
477 30 µL of passive lysis buffer (Promega) followed by one freeze-thaw cycle. An LB942 TriStar  
478 luminometer (Berthold Technologies) was used to measure the luciferase activity of each well  
479 after the addition of 100 µL of luciferin buffer (15mM MgSO<sub>4</sub>, 15mM KPO<sub>4</sub> [pH 7.8], 1mM ATP,  
480 and 1mM dithiothreitol) and 50 µL of 1mM d-luciferin potassium salt (Prolume). The neutralization  
481 half-maximal inhibitory dilution (ID<sub>50</sub>) represents the plasma dilution to inhibit 50% of the infection  
482 of 293T-ACE2 cells by pseudoviruses.

483

## 484 **QUANTIFICATION AND STATISTICAL ANALYSIS**

### 485 **Statistical analysis**

486 Symbols represent biologically independent samples from SOTR and HCW. Lines connect data  
487 from the same donor. Statistics were analyzed using GraphPad Prism version 8.0.1 (GraphPad,  
488 San Diego, CA). Every dataset was tested for statistical normality and this information was used  
489 to apply the appropriate (parametric or nonparametric) statistical test. Differences in responses  
490 for the same donor after the second and third dose of mRNA vaccine were performed using Mann-  
491 Whitney tests. Differences in responses between HCW and SOTR at D2 or D3 were measured  
492 by Kruskal-Wallis tests. P values < 0.05 were considered significant; significance values are  
493 indicated as \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001, \*\*\*\* p < 0.0001. Spearman's R correlation  
494 coefficient was applied for correlations. Statistical tests were two-sided and p < 0.05 was  
495 considered significant.

496

### 497 **Software scripts and visualization**

498 Edge bundling graphs were generated in undirected mode in R and RStudio using ggraph, igraph,  
499 tidyverse, and RColorBrewer packages (R Core Team, 2014). Edges are only shown if p < 0.05,  
500 and nodes are sized according to the connecting edges' r values. Nodes are color-coded  
501 according to groups of variables.

502

## 503 **SUPPLEMENTAL INFORMATION**

504 Supplemental information can be found online at ...



## 505 REFERENCES

- 506 Anand, S.P., Prévost, J., Richard, J., Perreault, J., Tremblay, T., Drouin, M., Fournier, M.-J.,  
507 Lewin, A., Bazin, R., and Finzi, A. (2020). High-throughput detection of antibodies targeting the  
508 SARS-CoV-2 Spike in longitudinal convalescent plasma samples (*Microbiology*).
- 509 Anand, S.P., Prévost, J., Nayrac, M., Beaudoin-Bussièrès, G., Benlarbi, M., Gasser, R., Brassard,  
510 N., Laumaea, A., Gong, S.Y., Bourassa, C., et al. (2021). Longitudinal analysis of humoral  
511 immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-  
512 symptom onset. *Cell Rep. Med.* 100290. <https://doi.org/10.1016/j.xcrm.2021.100290>.
- 513 Ariën, K.K., Heyndrickx, L., Michiels, J., Vereecken, K., Van Lent, K., Coppens, S., Willems, B.,  
514 Pannus, P., Martens, G.A., Van Esbroeck, M., et al. (2022). Three doses of BNT162b2 vaccine  
515 confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant. *Npj Vaccines* 7,  
516 1–3. <https://doi.org/10.1038/s41541-022-00459-z>.
- 517 AST (2022). Joint Statement about COVID-19 Vaccination in Organ Transplant Candidates and  
518 Recipients, [https://www.myast.org/sites/default/files/03-13-22%20ISHLT-AST-](https://www.myast.org/sites/default/files/03-13-22%20ISHLT-AST-ASTS%20joint%20society%20guidance%20vaccine_v9.pdf)  
519 [ASTS%20joint%20society%20guidance%20vaccine\\_v9.pdf](https://www.myast.org/sites/default/files/03-13-22%20ISHLT-AST-ASTS%20joint%20society%20guidance%20vaccine_v9.pdf).
- 520 Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector,  
521 S.A., Roupheal, N., Creech, C.B., et al. (2021). Efficacy and Safety of the mRNA-1273 SARS-  
522 CoV-2 Vaccine. *N. Engl. J. Med.* 384, 403–416. <https://doi.org/10.1056/NEJMoa2035389>.
- 523 Beaudoin-Bussièrès, G., Laumaea, A., Anand, S.P., Prévost, J., Gasser, R., Goyette, G.,  
524 Medjahed, H., Perreault, J., Tremblay, T., Lewin, A., et al. (2020). Decline of Humoral Responses  
525 against SARS-CoV-2 Spike in Convalescent Individuals. *MBio* 11.  
526 <https://doi.org/10.1128/mBio.02590-20>.
- 527 Beaudoin-Bussièrès, G., Richard, J., Prévost, J., Goyette, G., and Finzi, A. (2021). A new flow  
528 cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-  
529 expressing cells. *STAR Protoc.* 2, 100851. <https://doi.org/10.1016/j.xpro.2021.100851>.
- 530 Björkman, C., Näslund, K., Stenlund, S., Maley, S.W., Buxton, D., and Ugglå, A. (1999). An IgG  
531 Avidity ELISA to Discriminate between Recent and Chronic *Neospora Caninum* Infection. *J. Vet.*  
532 *Diagn. Invest.* 11, 41–44. <https://doi.org/10.1177/104063879901100106>.
- 533 Caillard, S., Chavarot, N., Bertrand, D., Kamar, N., Thauinat, O., Moal, V., Masset, C., Hazzan,  
534 M., Gatault, P., Sicard, A., et al. (2021). Occurrence of severe COVID-19 in vaccinated transplant  
535 patients. *Kidney Int.* 100, 477–479. <https://doi.org/10.1016/j.kint.2021.05.011>.
- 536 Chan, C.M., Tse, H., Wong, S.S.Y., Woo, P.C.Y., Lau, S.K.P., Chen, L., Zheng, B.J., Huang, J.D.,  
537 and Yuen, K.Y. (2009). Examination of seroprevalence of coronavirus HKU1 infection with S  
538 protein-based ELISA and neutralization assay against viral spike pseudotyped virus. *J. Clin. Virol.*  
539 45, 54–60. <https://doi.org/10.1016/j.jcv.2009.02.011>.
- 540 Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S.Y., Boutin, M., Bourassa, C., Beaudoin-  
541 Bussièrès, G., Bo, Y., Ding, S., Laumaea, A., et al. (2022). SARS-CoV-2 Omicron Spike  
542 recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week  
543 interval between doses. *Cell Rep.* 110429. <https://doi.org/10.1016/j.celrep.2022.110429>.



- 544 CST (2022). National Transplant Consensus Guidance on COVID-19 Vaccine, chrome-  
545 [https://www.cst-](https://www.cst-transplant.ca/_Library/Coronavirus/National_Transplant_Consensus_Guidance_on_COVID_Vaccine_2022_1_final_1_.pdf)  
546 [transplant.ca/\\_Library/Coronavirus/National\\_Transplant\\_Consensus\\_Guidance\\_on\\_COVID\\_Va](https://www.cst-transplant.ca/_Library/Coronavirus/National_Transplant_Consensus_Guidance_on_COVID_Vaccine_2022_1_final_1_.pdf)  
547 [ccine\\_2022\\_1\\_final\\_1\\_.pdf](https://www.cst-transplant.ca/_Library/Coronavirus/National_Transplant_Consensus_Guidance_on_COVID_Vaccine_2022_1_final_1_.pdf).
- 548 Danziger-Isakov, L., Blumberg, E.A., Manuel, O., and Sester, M. (2021). Impact of COVID-19 in  
549 solid organ transplant recipients. *Am. J. Transplant.* 21, 925–937.  
550 <https://doi.org/10.1111/ajt.16449>.
- 551 Fialová, L., Petráčková, M., and Kuchař, O. (2017). Comparison of different enzyme-linked  
552 immunosorbent assay methods for avidity determination of antiphospholipid antibodies. *J. Clin.*  
553 *Lab. Anal.* 31, e22121. <https://doi.org/10.1002/jcla.22121>.
- 554 Gong, S.Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina, D.,  
555 Goyette, G., Gendron-Lepage, G., et al. (2021). Contribution of single mutations to selected  
556 SARS-CoV-2 emerging variants spike antigenicity. *Virology* 563, 134–145.  
557 <https://doi.org/10.1016/j.virol.2021.09.001>.
- 558 Jennewein, M.F., MacCamy, A.J., Akins, N.R., Feng, J., Homad, L.J., Hurlburt, N.K., Seydoux,  
559 E., Wan, Y.-H., Stuart, A.B., Edara, V.V., et al. (2021). Isolation and characterization of cross-  
560 neutralizing coronavirus antibodies from COVID-19+ subjects. *Cell Rep.* 36, 109353.  
561 <https://doi.org/10.1016/j.celrep.2021.109353>.
- 562 Kumar, D., Blumberg, E.A., Danziger-Isakov, L., Kotton, C.N., Halasa, N.B., Ison, M.G., Avery,  
563 R.K., Green, M., Allen, U.D., Edwards, K.M., et al. (2011). Influenza Vaccination in the Organ  
564 Transplant Recipient: Review and Summary Recommendations†. *Am. J. Transplant.* 11, 2020–  
565 2030. <https://doi.org/10.1111/j.1600-6143.2011.03753.x>.
- 566 Kumar, S., Thambiraja, T.S., Karuppanan, K., and Subramaniam, G. (2022). Omicron and Delta  
567 variant of SARS-CoV-2: A comparative computational study of spike protein. *J. Med. Virol.* 94,  
568 1641–1649. <https://doi.org/10.1002/jmv.27526>.
- 569 Lauring, A.S., Tenforde, M.W., Chappell, J.D., Gaglani, M., Ginde, A.A., McNeal, T., Ghamande,  
570 S., Douin, D.J., Talbot, H.K., Casey, J.D., et al. (2022). Clinical severity of, and effectiveness of  
571 mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the  
572 United States: prospective observational study. *BMJ* 376, e069761. [https://doi.org/10.1136/bmj-](https://doi.org/10.1136/bmj-2021-069761)  
573 [2021-069761](https://doi.org/10.1136/bmj-2021-069761).
- 574 Li, W., Chen, Y., Prévost, J., Ullah, I., Lu, M., Gong, S.Y., Tauzin, A., Gasser, R., Vézina, D.,  
575 Anand, S.P., et al. (2022). Structural basis and mode of action for two broadly neutralizing  
576 antibodies against SARS-CoV-2 emerging variants of concern. *Cell Rep.* 38, 110210.  
577 <https://doi.org/10.1016/j.celrep.2021.110210>.
- 578 Meulen, J. ter, Brink, E.N. van den, Poon, L.L.M., Marissen, W.E., Leung, C.S.W., Cox, F.,  
579 Cheung, C.Y., Bakker, A.Q., Bogaards, J.A., Deventer, E. van, et al. (2006). Human Monoclonal  
580 Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants.  
581 *PLOS Med.* 3, e237. <https://doi.org/10.1371/journal.pmed.0030237>.
- 582 Miele, M., Busà, R., Russelli, G., Sorrentino, M.C., Di Bella, M., Timoneri, F., Mularoni, A.,  
583 Panarello, G., Vitulo, P., Conaldi, P.G., et al. (2021). Impaired anti-SARS-CoV-2 Humoral and  
584 Cellular Immune Response induced by Pfizer-BioNTech BNT162b2 mRNA Vaccine in Solid

- 585 Organ Transplanted Patients. *Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl.*  
586 *Surg.* <https://doi.org/10.1111/ajt.16702>.
- 587 Nayrac, M., Dubé, M., Sannier, G., Nicolas, A., Marchitto, L., Tastet, O., Tauzin, A., Brassard, N.,  
588 Beaudoin-Bussièrès, G., Vézina, D., et al. (2021). Temporal associations of B and T cell immunity  
589 with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. *BioRxiv Prepr.*  
590 *Serv. Biol.* 2021.12.18.473317. <https://doi.org/10.1101/2021.12.18.473317>.
- 591 Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N., Erster, O., Cohen, C., Kreiss, Y., Alroy-Preis, S.,  
592 Regev-Yochay, G., Mendelson, E., et al. (2022). Third BNT162b2 Vaccination Neutralization of  
593 SARS-CoV-2 Omicron Infection. *N. Engl. J. Med.* 386, 492–494.  
594 <https://doi.org/10.1056/NEJMc2119358>.
- 595 Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N.,  
596 Faustini, S., Al-Taei, S., Moore, S.C., et al. (2021). Immunogenicity of standard and extended  
597 dosing intervals of BNT162b2 mRNA vaccine. *Cell* 184, 5699–5714.e11.  
598 <https://doi.org/10.1016/j.cell.2021.10.011>.
- 599 Pereira, M.R., Mohan, S., Cohen, D.J., Husain, S.A., Dube, G.K., Ratner, L.E., Arcasoy, S.,  
600 Aversa, M.M., Benvenuto, L.J., Dadhania, D.M., et al. (2020). COVID-19 in solid organ transplant  
601 recipients: Initial report from the US epicenter. *Am. J. Transplant.* 20, 1800–1808.  
602 <https://doi.org/10.1111/ajt.15941>.
- 603 Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland,  
604 W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2021). Considerable escape of SARS-CoV-2  
605 Omicron to antibody neutralization. *Nature* 1–7. <https://doi.org/10.1038/s41586-021-04389-z>.
- 606 Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez  
607 Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA  
608 Covid-19 Vaccine. *N. Engl. J. Med.* 383, 2603–2615. <https://doi.org/10.1056/NEJMoa2034577>.
- 609 Prévost, J., Gasser, R., Beaudoin-Bussièrès, G., Richard, J., Duerr, R., Laumaea, A., Anand,  
610 S.P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020). Cross-Sectional Evaluation of Humoral  
611 Responses against SARS-CoV-2 Spike. *Cell Rep. Med.* 1, 100126.  
612 <https://doi.org/10.1016/j.xcrm.2020.100126>.
- 613 R Core Team (2014). R: A language and environment for statistical computing. R Foundation for  
614 Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/>.
- 615 Rabinowich, L., Grupper, A., Baruch, R., Ben-Yehoyada, M., Halperin, T., Turner, D., Katchman,  
616 E., Levi, S., Houri, I., Lubezky, N., et al. (2021). Low immunogenicity to SARS-CoV-2 vaccination  
617 among liver transplant recipients. *J. Hepatol.* 75, 435–438.  
618 <https://doi.org/10.1016/j.jhep.2021.04.020>.
- 619 Rees, E.M., Waterlow, N.R., Lowe, R., and Kucharski, A.J. (2021). Estimating the duration of  
620 seropositivity of human seasonal coronaviruses using seroprevalence studies. *Wellcome Open*  
621 *Res.* 6, 138. <https://doi.org/10.12688/wellcomeopenres.16701.3>.
- 622 Richardson, S.I., Manamela, N.P., Motsoeneng, B.M., Kaldine, H., Ayres, F., Makhado, Z.,  
623 Mennen, M., Skelem, S., Williams, N., Sullivan, N.J., et al. (2022). SARS-CoV-2 Beta and Delta

- 624 variants trigger Fc effector function with increased cross-reactivity. *Cell Rep. Med.* 3, 100510.  
625 <https://doi.org/10.1016/j.xcrm.2022.100510>.
- 626 Rincon-Arevalo, H., Choi, M., Stefanski, A.-L., Halleck, F., Weber, U., Szelinski, F., Jahrsdörfer,  
627 B., Schrezenmeier, H., Ludwig, C., Sattler, A., et al. (2021). Impaired humoral immunity to SARS-  
628 CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. *Sci. Immunol.* 6,  
629 eabj1031. <https://doi.org/10.1126/sciimmunol.abj1031>.
- 630 Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z., Gaebler,  
631 C., Caskey, M., Nussenzweig, M.C., et al. (2022). Plasma Neutralization of the SARS-CoV-2  
632 Omicron Variant. *N. Engl. J. Med.* 386, 599–601. <https://doi.org/10.1056/NEJMc2119641>.
- 633 Sheikhi, K., Shirzadfar, H., and Sheikhi, M. (2020). A Review on Novel Coronavirus (Covid-19):  
634 Symptoms, Transmission and Diagnosis Tests. *Res. Infect. Dis. Trop. Med.* 2, 1–8.  
635 <https://doi.org/10.33702/ridtm.2020.2.1.1>.
- 636 Stucchi, R.S.B., Lopes, M.H., Kumar, D., and Manuel, O. (2018). Vaccine Recommendations for  
637 Solid-Organ Transplant Recipients and Donors. *Transplantation* 102, S72.  
638 <https://doi.org/10.1097/TP.0000000000002012>.
- 639 Stumpf, J., Siepmann, T., Lindner, T., Karger, C., Schwöbel, J., Anders, L., Faulhaber-Walter, R.,  
640 Schewe, J., Martin, H., Schirutschke, H., et al. (2021). Humoral and cellular immunity to SARS-  
641 CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter  
642 observational study using mRNA-1273 or BNT162b2 mRNA vaccine. *Lancet Reg. Health - Eur.*  
643 9, 100178. <https://doi.org/10.1016/j.lanepe.2021.100178>.
- 644 Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S.Y., Gasser, R., Beaudoin-Bussièrès, G., Brassard,  
645 N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021). A single dose of the SARS-CoV-2 vaccine  
646 BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. *Cell Host Microbe*  
647 0. <https://doi.org/10.1016/j.chom.2021.06.001>.
- 648 Tauzin, A., Gong, S.Y., Painter, M.M., Goel, R.R., Chatterjee, D., Beaudoin-Bussièrès, G.,  
649 Marchitto, L., Boutin, M., Laumaea, A., Okeny, J., et al. (2022a). A boost with SARS-CoV-2  
650 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between  
651 the first two doses. 2022.04.18.22273967. <https://doi.org/10.1101/2022.04.18.22273967>.
- 652 Tauzin, A., Gendron-Lepage, G., Nayrac, M., Anand, S.P., Bourassa, C., Medjahed, H., Goyette,  
653 G., Dubé, M., Bazin, R., Kaufmann, D.E., et al. (2022b). Evolution of Anti-RBD IgG Avidity  
654 Following SARS-CoV-2 Infection. *Viruses* 14, 532. <https://doi.org/10.3390/v14030532>.
- 655 Tauzin, A., Gong, S.Y., Beaudoin-Bussièrès, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L.,  
656 Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2022c). Strong humoral immune responses  
657 against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between  
658 doses. *Cell Host Microbe* 30, 97-109.e5. <https://doi.org/10.1016/j.chom.2021.12.004>.
- 659 Tseng, H.F., Ackerson, B.K., Luo, Y., Sy, L.S., Talarico, C.A., Tian, Y., Bruxvoort, K.J., Tubert,  
660 J.E., Florea, A., Ku, J.H., et al. (2022). Effectiveness of mRNA-1273 against SARS-CoV-2  
661 Omicron and Delta variants. *Nat. Med.* 1–9. <https://doi.org/10.1038/s41591-022-01753-y>.
- 662 Ullah, I., Prévost, J., Ladinsky, M.S., Stone, H., Lu, M., Anand, S.P., Beaudoin-Bussièrès, G.,  
663 Symmes, K., Benlarbi, M., Ding, S., et al. (2021). Live imaging of SARS-CoV-2 infection in mice

664 reveals that neutralizing antibodies require Fc function for optimal efficacy. *Immunity* S1074-  
665 7613(21)00347-2. <https://doi.org/10.1016/j.immuni.2021.08.015>.

666 Yoon, S.K., Hegmann, K.T., Thiese, M.S., Burgess, J.L., Ellingson, K., Lutrick, K., Olsho, L.E.W.,  
667 Edwards, L.J., Sokol, B., Caban-Martinez, A.J., et al. (2022). Protection with a Third Dose of  
668 mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. *N. Engl. J. Med.* 0, null.  
669 <https://doi.org/10.1056/NEJMc2201821>.

670





Figure 1




Figure 2




Figure 3





Figure 4



After the second dose



After the third dose






Figure 5



**Figure S1 : Recognition of SARS-CoV-2 Spike variants by vaccinated solid organ transplant recipients, Related to Figure 2.**

293T cells were transfected with the indicated full-length S from different SARS-CoV-2 variants and stained with the CV3-25 Ab or with plasma from HCW (**A**) or transplant recipients (**B-E**) collected after the second and third doses of mRNA vaccine. The values represent the MFI normalized by the CV3-25 Ab. Symbols represent biologically independent samples from transplant recipients and HCW. Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means  $\pm$  SEM. (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ; \*\*\*\*  $p < 0.0001$ ; ns, non-significant).



**Figure S2 : Neutralization of SARS-CoV-2 Spike variants by vaccinated solid organ transplant recipients, Related to Figure 3.**

Neutralizing activity was measured by incubating pseudoviruses bearing SARS-CoV-2 S glycoproteins with serial dilutions of plasma from HCW (A) and transplant recipients (B-E) collected after the second and third doses of mRNA vaccine for 1 h at 37°C before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution ( $ID_{50}$ ) values were determined using a normalized non-linear regression using GraphPad Prism software. Symbols represent biologically independent samples from transplant recipients and HCW. Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means  $\pm$  SEM. (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ ; \*\*\*\*  $p < 0.0001$ ; ns, non-significant).